Research
Macro partitioning
Incretin receptor activators (GLP-1RA and GIP/GLP-1 dual agonists) cause a reduction in skeletal muscle mass (SMM) that is proportional to fat loss, with approximately 5% of lean body mass lost for every 10% reduction in total body weight, potentially leading to sarcopenia in a subset of treated patients.
If you are taking GLP-1RA or similar weight-loss medications, be aware that you will lose some muscle along with fat. To minimize this, engage in structured exercise programs and discuss monitoring your muscle mass with your doctor, especially if you are older or have existing frailty.
GoodSupportsHIGH confidence
Across studies of dietary weight loss, GLP- 1RA, and bariatric surgery, the relationship between the fraction of body weight lost and the fraction of lean body mass lost is linear, with somewhat limited data showing approximately 5% such loss for every 10% body weight reduction [10].
Why this rating
Based on a meta-analysis of 36 studies for bariatric surgery and a meta-analysis of 27 studies for GLP-1RA, though the author notes variability.
Source
Monitoring Sarcopenia With Incretin Receptor Activator Treatment
Zachary T. Bloomgarden · Journal of Diabetes · 2025
narrative_reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →